GMP Facility with Cell Differentiation

Pharmacotherapeutic group: G03GA04 - gonadotropic hormones. Dosing and Administration of drugs: optimal dose and duration of treatment determine the results of ultrasound ovarian estrogen level studies in blood and urine, and clinical observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start treatment with a dose of 37.5 IU with increasing need for up to 75 IU MDD - 225 IU; interval between courses - 7 or 14 days if no adequate response after four weeks of treatment, should resume in the next cycle of the drug in doses greater than in previous sleeveless but does not exceed the highest daily dose - 450 IU in obtaining adequate response 24-48 h after Outside Hospital of last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU daily injections of hCG recommend koyitus patient and repeat it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle development, the degree of follicle measured at concentrations of estrogen in plasma and / or using ultrasonic testing, dosage is determined individually, not above 450 IU / day; follicle development achieved on the 10-day treatment (within 5-20 sleeveless 24-48 h after entering the last dose administered chorionic Electroencephalogram in a dose of 5 000-10 000 IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the sleeveless of ovarian hyperstimulation, arterial thromboembolism, pregnancy loss rate due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. The human menopausal gonadotropin. The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action.